Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

Key Points

Key points are not available for this paper at this time.

Abstract

In this trial, canakinumab was effective in controlling and preventing flares in patients with colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, and TRAPS. (Funded by Novartis; CLUSTER ClinicalTrials.gov number, NCT02059291 .).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Benedetti et al. (Wed,) studied this question.

synapsesocial.com/papers/69dff696b28b234044e9c0d0 https://doi.org/https://doi.org/10.1056/nejmoa1706314

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever2010 · 76 citations
2Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry2015 · 6 citations
3Lack of isoprenoid products raises ex vivo interleukin‐1β secretion in hyperimmunoglobulinemia D and periodic fever syndrome2002 · 172 citations
4<b>Immunoglobulin D enhances the release of tumour necrosis factor‐α, and interleukin‐1β as well as interleukin‐1 receptor antagonist from human mononuclear cells</b>1996 · 90 citations
5Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study2016 · 104 citations

Bookmark

View Full Paper